TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $9.04 million for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35). The company had revenue of $8.26 million for the quarter, compared to analysts' expectations of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
TriSalus Life Sciences Stock Performance
Shares of TriSalus Life Sciences stock opened at $5.07 on Wednesday. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.24. The company has a market cap of $163.62 million, a price-to-earnings ratio of -2.04 and a beta of 0.50. The business's 50 day moving average price is $5.40 and its 200 day moving average price is $4.98.
Wall Street Analyst Weigh In
A number of brokerages recently commented on TLSI. Canaccord Genuity Group reiterated a "buy" rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Lake Street Capital began coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a "buy" rating and a $10.00 target price on the stock. Finally, Roth Mkm restated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $10.93.
View Our Latest Report on TLSI
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
